Hacker, K., Thomas, S., Lightfoot, M., Arend, R. C., Moore, K. N., Washington, C., … Pothuri, B. (2025). 1152P Cyclin E1 amplification (CCNE1amp) is associated with race and poor outcomes in endometrial cancer (EC). In Annals of Oncology (Vol. 36, pp. S714–S714). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.1788

Hacker, K., S. Thomas, M. Lightfoot, R. C. Arend, K. N. Moore, C. Washington, P. H. Thaker, et al. “1152P Cyclin E1 amplification (CCNE1amp) is associated with race and poor outcomes in endometrial cancer (EC).” In Annals of Oncology, 36:S714–S714. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.1788.

Hacker K, Thomas S, Lightfoot M, Arend RC, Moore KN, Washington C, et al. 1152P Cyclin E1 amplification (CCNE1amp) is associated with race and poor outcomes in endometrial cancer (EC). In: Annals of Oncology. Elsevier BV; 2025. p. S714–S714.

Hacker, K., et al. “1152P Cyclin E1 amplification (CCNE1amp) is associated with race and poor outcomes in endometrial cancer (EC).” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S714–S714. Crossref, doi:10.1016/j.annonc.2025.08.1788.

Hacker K, Thomas S, Lightfoot M, Arend RC, Moore KN, Washington C, Thaker PH, Crafton S, Backes F, Wright J, Jackson AL, Corr BR, Castellano T, Bae-Jump V, Maxwell G, Puechl AM, Ko E, Secord AA, Pothuri B. 1152P Cyclin E1 amplification (CCNE1amp) is associated with race and poor outcomes in endometrial cancer (EC). Annals of Oncology. Elsevier BV; 2025. p. S714–S714.